Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine renal protection in living donor kidney transplantation
ChiCTR2100045802Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine in end-stage kidney disease (ESKD), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Kidney injury molecule-1, Neutrophil gelatinase-associated lipocalin and 2 more. Started Apr 2021; status: recruiting.
02
Drugs
dexmedetomidine
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2100045802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045802.